Farmak, the leader of the domestic pharmaceutical industry, has launched a website of its Representative Office in Kyrgyzstan, which can be found at farmak.kg.
Farmak’s Representative Office in Kyrgyzstan has been working since February 2013. Although it is worth mentioning that Farmak’s products were launched at Kyrgyzstan market back in mid-1990s. According to the analytical pharmaceutical database, IMS, today Farmak is in TOP-20 largest pharmaceutical manufacturers at Kyrgyzstan market, ranking 20th with a market share of 1.54 % (monetary value, USD), improving its position in the rating by 29 points, from the 49th in 2013.
The resource has a convenient Russian interface and a clear structure that allows finding all the necessary information in maximum three clicks.
Maya Sandulska, Head of Department for Marketing of Export Markets, Farmak, says, “The website of our Company’s Representative Office in Kyrgyzstan will enable to enhance communication with the target audience in the local market. It will enable prompt informing of new drugs marketed in Kyrgyzstan, social projects implemented by the Representative Office, activities of the Representative Office and the Company itself, vacancies and quick feedback from patients, potential partners, companies and institutions interested in cooperation with the Representative Office”.
In total, the Fund donated over UAH 4 million to fight the COVID-19 pandemic in the Ruzhynskyi district, as well as to reconstruct and equip a first-aid post in Nemyryntsi village As part of the anti-pandemic campaign, the Zhebrivski Family Charitable Foundation provided the Municipal Non-Commercial Enterprise “District Central Hospital” of the Ruzhynskyi Di...
The video presents a story of a typical day of several Farmak employees who get up before dawn, take care of their loved ones and go to work to fulfil an important mission. In such a simple form, the director portrayed Farmak as the Company with a soul, where employees are ordinary people, with their […]
Due to the new manufacturing facility, the Company will increase the manufacturing of sterile liquid medicinal products, the demand for which has significantly grown during the pandemic. The new manufacturing facility is a seven-storey building with over 20 units of main technological equipment and about 100 engineering equipment. It was built from the groun...